The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Phase III trial of first-line SHR-1701 with chemotherapy in HER2- G/GEJA
Radka Obermannova, MD, PhD, Masaryk University, Brno, Czech Republic, discusses a Phase III trial (NCT04950322) of SHR-1701, a bifunctional PD-L1 and TGF-βIIR targeting agent, with chemotherapy as first-line treatment for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). In patients with PD-L1 CPS ≥5 tumors, SHR-1701 plus chemotherapy significantly improved overall survival (OS) versus placebo. Progression-free survival, objective response rates, and duration of response were similarly improved, with manageable safety profiles in both groups. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
